Pharmaceutical

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate…

4 days ago

Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has…

4 days ago

Positive results advance peanut tablet to phase II development

ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding…

4 days ago

Polyrizon’s Moving Forward with Expected 2025 Clinical Trial – Entered Manufacturing Agreement for its PL-14 Allergy Blocker

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer…

4 days ago

ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051

When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and…

4 days ago

PillSafe Founders’ Interview Featured on Bloomberg, Fox Business, and Nasdaq

The interview with Dr. John Barr and Jim Patton tackles medication safety and how PillSafe Technologies secures prescriptions, prevents abuse,…

5 days ago

Theranexus and Exeltis (Insud Pharma) Announce Licensing Agreement to Commercialize Theranexus Tx01 for Two Rare Neurological Disorders

Exeltis will be granted an exclusive license to market and distribute Theranexus' novel formulation TX01 for the treatment of two…

5 days ago

Theranexus Presents an Update of its Cash Position and Financing Horizon

LYON, FRANCE / ACCESSWIRE / December 17, 2024 / Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological…

5 days ago

Ubie Growth in 2024 Driven by Industry Leading Recognition, Collaborations with Patient Advocacy Groups and an Expanded Reach of More Than 4 Million Users

Strategic investment from Google and acceptance into Mayo Clinic Platform Accelerate program show an increasing understanding of Ubie's value to patients…

5 days ago